Clinical Trials
35 trialsDecitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Intervention for Fatigue in HCT Recipients
Massachusetts General Hospital
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Octapharma
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Thomas Jefferson University
TUD-APOLLO-064
Technische Universität Dresden
PROXIMUS
Boston Children's Hospital
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
National Institutes of Health Clinical Center (CC)
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
CA2D
University Hospital, Bordeaux
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
University of Nebraska
EscrimHEMA
University Hospital, Angers
CLARA
Hospices Civils de Lyon
NiloPost-STIM
University Hospital, Bordeaux
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
STIM 2
University Hospital, Bordeaux
The Oronasal Microbiota in Pediatric Oncology Patients
St. Jude Children's Research Hospital
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Massachusetts General Hospital
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Viale-a
AbbVie
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center